Literature DB >> 29778994

Heart rate changes during positive pressure ventilation after asphyxia-induced bradycardia in a porcine model of neonatal resuscitation.

Maria Liza Espinoza1,2, Po-Yin Cheung2,3, Tze-Fun Lee2,3, Megan O'Reilly2,3, Georg M Schmölzer2,3.   

Abstract

BACKGROUND: The Neonatal Resuscitation Program (NRP) states that if adequate positive pressure ventilation (PPV) was given for a low heart rate (HR), the infant's HR should increase within the first 15 s of PPV.
OBJECTIVE: To assess changes in HR in piglets with asphyxia-induced bradycardia.
METHODS: Term newborn piglets (n=30) were anaesthetised, intubated, instrumented and exposed to 50 min normocapnic hypoxia followed by asphyxia. Asphyxia was achieved by clamping the tube until severe bradycardia (defined as HR at <25% of baseline). This was followed by 30 s adequate PPV and chest compression thereafter. Changes in HR during the 30 s of PPV were assessed and divided into four epochs (0-10 s, 5-15 s, 10-20 s and 20-30 s, respectively).
RESULTS: Increase in HR >100/min was observed in 6/30 (20%) after 30 s of PPV. Within the epochs 0-10 s, 5-15 s or 10-20 s no piglet had an increase in HR >100/min. Additional 10/30 (33%) had a >10% increase in HR.
CONCLUSION: In contrast to NRP recommendation, adequate PPV does not increase HR within 15 s after ventilation in piglets with asphyxia-induced bradycardia. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  asphyxia; heart rate; infants; neonatal resuscitation; newborn

Mesh:

Year:  2018        PMID: 29778994     DOI: 10.1136/archdischild-2017-314637

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  1 in total

1.  Effectiveness of Nursing Risk Management in Neonatal Asphyxia Resuscitation Care.

Authors:  Zhen Ye; Wenjun Wang; Peili Sun
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-03       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.